Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy
Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment (TME). Mavrostobart fully inhibits the enzyme activities of both soluble and membrane-bound CD73, unlike several other anti-CD73 antibodies which exhibit incomplete inhibition. Moreover, at higher concentrations, no loss of inhibition or "hook effect" is observed with mavrostobart. Hence, mavrostobart addresses the limitations of current CD73 inhibitors and is expected to increase antitumor immune activation, and potentially offer a new treatment option for cancer patients.
The multi-center Phase I/II clinical trial of mavrostobart (NCT05431270), known as the MORNINGSTAR study, is currently evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of mavrostobart alone and in combination with a PD-1 Inhibitor or chemotherapy. A Phase I clinical trial of mavrostobart is also ongoing in China (CTR20242381).
ABOUT PHANES THERAPEUTICS
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I/II clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, mavrostobart (PT199), the TWINPEAK study with spevatamig (PT886) and the SKYBRIDGE study with peluntamig (PT217). Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug designations as well as Fast Track designations by the FDA.
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit www.phanesthera.com
For business development or media inquiries, please contact bd@phanestx.com or media@phanestx.com, respectively.
View original content to download multimedia:https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-mavrostobart-pt199-in-combination-with-chemotherapy-302464552.html
SOURCE Phanes Therapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
GeeTest Releases 2025 E-commerce Industry Security White Paper to Strengthen Online Retail Protection
WUHAN, China, July 25, 2025 /PRNewswire/ -- GeeTest, a global leader in bot mitigation and business security, has released its 2025 E-commerce Industry Security White Paper, offering a comprehensive analysis of the mounting cybersecurity threats facing digital commerce and providing practical, scenario-based strategies to address them. Empowering E-commerce Platforms to Defend Against Evolving Threats With the rapid expansion of the digital economy, e-commerce has emerged as a key driver of global growth. However, it is increasingly vulnerable to sophisticated, automated cyberattacks. In 2024, over 65% of platforms were targeted by bot-driven registration abuse, while 47% of promotional campaigns suffered resource hijacking. Transaction fraud also rose by 18% year over year, eroding platform performance and user trust. In response, GeeTest delivers a full-path, intelligence-driven security architecture designed to safeguard every phase of the user journey—from registration to checkout. Backed by 13 years of innovation, GeeTest's solutions integrate behavioral verification, device fingerprinting, and an adaptive, risk-based business rules decision engine to support enterprises across a wide range of digital industries. What Awaits You in This White Paper This white paper serves as both a strategic guide and a technical resource for security and operations teams. Key highlights include: Market Overview: Analysis of how rapid e-commerce expansion is fueling new security challenges. Pain Points & Risks: Insights into challenges such as bot scalping, payment fraud, and the inadequacy of traditional CAPTCHA-based verification. Full-Path Security Solution: GeeTest's holistic protection across registration, login, transactions, coupons, and promotions. Case Studies: Real-world examples of successful deployments on global e-commerce platforms. Future Outlook: Emerging trends in AI-driven security, privacy compliance, and SECaaS (Security-as-a-Service) ecosystem collaborations. By aligning robust security controls with user experience and regulatory needs, GeeTest empowers online businesses to achieve long-term growth and resilience in an evolving digital environment. The full 2025 E-commerce Industry Security White Paper is available at: About GeeTest: Founded in 2012, GeeTest is a leading provider of CAPTCHA and bot management solutions. The company protects websites, mobile apps, and APIs from automated threats such as account takeover (ATO), credential stuffing, and web scalping. With over 13 years of innovation in human-bot verification, GeeTest now serves more than 360,000 enterprises across industries including e-commerce, blockchain, and online gaming. View original content to download multimedia: SOURCE GeeTest Sign in to access your portfolio
Yahoo
30 minutes ago
- Yahoo
Phillips Edison & Company (PECO) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2025, Phillips Edison & Company, Inc. (PECO) reported revenue of $177.75 million, up 10.1% over the same period last year. EPS came in at $0.64, compared to $0.12 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $176.99 million, representing a surprise of +0.43%. The company delivered an EPS surprise of +1.59%, with the consensus EPS estimate being $0.63. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Phillips Edison & Company performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Rental income: $173.47 million versus $172.41 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.6% change. Revenues- Other property income: $0.97 million versus the two-analyst average estimate of $0.78 million. The reported number represents a year-over-year change of +37.2%. Revenues- Fees and management income: $3.32 million versus the two-analyst average estimate of $2.64 million. The reported number represents a year-over-year change of +31.5%. Net income (loss) per share- diluted: $0.10 versus $0.19 estimated by two analysts on average. View all Key Company Metrics for Phillips Edison & Company here>>> Shares of Phillips Edison & Company have returned +1% over the past month versus the Zacks S&P 500 composite's +5.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phillips Edison & Company, Inc. (PECO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Upstart Holdings, Inc. (UPST) Stock Drops Despite Market Gains: Important Facts to Note
Upstart Holdings, Inc. (UPST) closed the most recent trading day at $82.70, moving -1.7% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, added 0.18%. Shares of the company have appreciated by 34.74% over the course of the past month, outperforming the Finance sector's gain of 4.82%, and the S&P 500's gain of 5.71%. The investment community will be paying close attention to the earnings performance of Upstart Holdings, Inc. in its upcoming release. The company is slated to reveal its earnings on August 5, 2025. The company is predicted to post an EPS of $0.27, indicating a 258.82% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $225.3 million, indicating a 76.52% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates are projecting earnings of $1.58 per share and revenue of $1.02 billion, which would represent changes of +890% and +59.46%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Upstart Holdings, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Upstart Holdings, Inc. boasts a Zacks Rank of #3 (Hold). In terms of valuation, Upstart Holdings, Inc. is presently being traded at a Forward P/E ratio of 53.31. Its industry sports an average Forward P/E of 12.91, so one might conclude that Upstart Holdings, Inc. is trading at a premium comparatively. The Financial - Miscellaneous Services industry is part of the Finance sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Upstart Holdings, Inc. (UPST) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
